Outlook Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Outlook Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Sep 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-1.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 64% of Healthcare companies in United States.
Cash Cushion Ratio
−16%Debt, after subtracting cash, equals 16% of its market value (net debt).
Lower than 82% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Outlook Therapeutics, Inc. made a loss over the last year. Outlook Therapeutics, Inc. owes $1.40 for every $1 it owns. Outlook Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
LossOutlook Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-12.16Outlook Therapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$126 MThe total market value of all of Outlook Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeOutlook Therapeutics, Inc.'s net worth is negative ($10 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.40×Outlook Therapeutics, Inc. owes $1.40 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Dividend yield
NoneOutlook Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossOutlook Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-4416.2%Outlook Therapeutics, Inc. lost $4416 for every $100 of revenue.
Interest cover
Not coveredOutlook Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Sep 2025.
Cash vs debt
Net debtOutlook Therapeutics, Inc. had $22 M more debt than cash (net debt) at Sep 2025.
Questions
How much does Outlook Therapeutics, Inc. owe compared with what it owns?
Outlook Therapeutics, Inc. owes $1.40 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Does Outlook Therapeutics, Inc. pay a dividend?
No. Outlook Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.